Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

GeNO LLC Initiates Study of Inhaled NITROSYLâ„¢ Nitric Oxide in Idiopathic Pulmonary Fibrosis (PH-IPF) and Pulmonary Arterial Hypertension (PAH) Patients

March 22, 2011 By Bio-Medicine.Org

COCOA, Fla., March 22, 2011 /PRNewswire/ — GeNO LLC (www.genollc.com), a privately
held, advanced development-stage technology company, today
announced commencement of  the PHiano Study: A Phase 2,
Dose-Escalation Trial for the Treatment of Pulmonary Hypertension
in patients with Pulmonary Arterial Hypertension (PAH) and
Pulmonary Hypertension secondary to Idiopathic Pulmonary Fibrosis
(PH-IPF) using Inhaled NITROSYL™ nitric oxide (NO).  The
first patient was successfully dosed at Creighton University
Medical Center. This trial will be conducted at multiple clinical
sites in the US, and is expected to enroll up to 75 patients.
 It is designed to investigate the safety and efficacy of
various doses of inhaled nitric oxide (NO), up to a maximum of 80
ppm, delivered for up to 150 minutes with GeNO’s
stand-alone NITROSYL™ system in subjects with WHO
Group 1 PAH and WHO Group 3 PH-IPF undergoing right heart
catheterization (RHC).

The primary objective of the PHiano study is to identify the
minimally effective dose and the maximum effective dose (dose
beyond which no further effect on pulmonary vascular resistance is
seen) of inhaled NITROSYL™ nitric oxide  as compared to
placebo.  Secondary objectives include assessing the safety
and tolerability of inhaled nitric oxide and evaluating the
pharmacokinetics of total nitrates/nitrites and methemoglobin
produced following inhalation. Additional study details can be
found on http://clinicaltrials.gov/
ClinicalTrials.gov Identifier: NCT01265888.  

GeNO’s stand-alone gas cylinder stores premixed nitric oxide as
nitrogen dioxide in either air or oxygen; however, this study will
administer nitrogen dioxide only in air. The gas is allowed to flow
through GeNO’s proprietary cartridge containing ascorbic acid,
which generates nitric oxide immediately prior to inhalation.
A

‘/>”/>

SOURCE

Related Articles Read More >

Johnson & Johnson Office of Digital Innovation Leader Peter Schulam
Imagining the future of cloud-connected medical devices with Johnson & Johnson leaders
Withings Body Scan
Withings plans launch for Body Scan smart scale platform
BinaxNow COVID-19 Ag Card
Time recognizes Abbott offerings among this year’s 100 best inventions
Koya Medical’s Dayspring device
Koya Medical reports positive early results in Dayspring lymphedema trial

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech